GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Operating Cash Flow per Share

Molecular Partners AG (XSWX:MOLN) Operating Cash Flow per Share : CHF-1.81 (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Operating Cash Flow per Share?

Molecular Partners AG's operating cash flow per share for the three months ended in Mar. 2024 was CHF-0.52. Molecular Partners AG's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was CHF-1.81.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -15.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Molecular Partners AG's Operating Cash Flow per Share or its related term are showing as below:

XSWX:MOLN' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -37.3   Med: -14.65   Max: 68.1
Current: -15.8

During the past 11 years, Molecular Partners AG's highest 3-Year average Operating Cash Flow per Share Growth Rate was 68.10% per year. The lowest was -37.30% per year. And the median was -14.65% per year.

XSWX:MOLN's 3-Year OCF Growth Rate is ranked worse than
71.34% of 1235 companies
in the Biotechnology industry
Industry Median: 3.3 vs XSWX:MOLN: -15.80

Molecular Partners AG Operating Cash Flow per Share Historical Data

The historical data trend for Molecular Partners AG's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Operating Cash Flow per Share Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -1.16 -2.93 3.56 -1.80

Molecular Partners AG Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.41 -0.40 -0.49 -0.52

Competitive Comparison of Molecular Partners AG's Operating Cash Flow per Share

For the Biotechnology subindustry, Molecular Partners AG's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Price-to-Operating-Cash-Flow falls into.



Molecular Partners AG Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Molecular Partners AG's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-59.005/32.771
=-1.80

Molecular Partners AG's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=-17.049/32.869
=-0.52

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus